Pro-Dex: Still A Buy, But Don't Chase
Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.
Pro-Dex: A Niche Surgical Tools Microcap Trading At A Discount
Pro-Dex manufactures powered surgical instruments for orthopedic, CMF, and thoracic procedures. This means that PDEX effectively combines OEM programs with a smaller catalog of industrial offerings. However, PDEX's revenue today remains highly concentrated. A single customer drives roughly 78% of sales.
Pro-Dex Valuation Is Attractive Despite Customer Risk
Pro-Dex Inc. is a specialized surgical device manufacturer with strong growth, efficient capital allocation, and high customer concentration risk. PDEX trades at ~16x recurrent earnings, which is fair and attractive for a small, non-concentrated position given its quality and growth prospects. Customer concentration remains the key risk, but contract renewals, sticky relationships, and secular healthcare tailwinds support continued growth.
Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Top Estimates
Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.75 per share a year ago.
Strength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?
ProDex (PDEX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here is Why Growth Investors Should Buy ProDex (PDEX) Now
ProDex (PDEX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ProDex (PDEX) Upgraded to Buy: Here's Why
ProDex (PDEX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity
Pro-Dex, Inc. experienced a 32% stock crash despite record Q3 2025 performance, presenting a buying opportunity for risk-tolerant investors. Q3 2025 revenue grew 22% YoY, with gross profit up 45% due to favorable product mix; operating income increased 64%. PDEX's PEG ratio of 0.27x indicates undervaluation compared to sector median, despite higher valuation multiples in other metrics.
Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates
Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.19 per share a year ago.
ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?
ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?
ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know
ProDex (PDEX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
